Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer  Anna Belilovski Rozenblum, MD, Maya.

Similar presentations


Presentation on theme: "Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer  Anna Belilovski Rozenblum, MD, Maya."— Presentation transcript:

1 Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer  Anna Belilovski Rozenblum, MD, Maya Ilouze, PhD, Elizabeth Dudnik, MD, Addie Dvir, MSc, Lior Soussan-Gutman, PhD, Smadar Geva, MSc, Nir Peled, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 2, Pages (February 2017) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Percentage of best response in 34 patients who received targeted therapy according to hybrid capture (HC)-based next-generation sequencing (NGS) results. Each bar represents one patient. Number of previous lines and genomic information guiding the targeted therapy in each case are elaborated. Nine of 43 patients not evaluable for tumor response at the time of tumor response were omitted. *Nonsensitizing EGFR mutation. NTRK1, neurotrophic tyrosine kinase receptor type 1 gene; VUS, variant of unknown sequence; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; RET, ret proto-oncogene; MET, Mesenchymal-epithelial transition factor receptor tyrosine kinase gene; NF1, neurofibromin 1 gene; ALK, anaplastic lymphoma receptor tyrosine kinase gene. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Percentage of best response for 13 patients in previous treatment lines versus in targeted therapy. Of 43 patients treated with targeted therapy after hybrid capture–based next-generation sequencing results, 23 had previous lines of treatment and 13 were evaluable for tumor response. Each vertical section represents one patient, encompassing one or two previous lines of treatment. Patient number and genomic information guiding the targeted therapy in each case is elaborated. The results of standard testing of all patients for EGFR/ALK alterations before hybrid capture–based next-generation sequencing were negative. ALK, anaplastic lymphoma receptor tyrosine kinase gene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; MET, Mesenchymal-epithelial transition factor receptor tyrosine kinase gene; NTRK1, neurotrophic tyrosine kinase receptor type 1 gene; RET, ret proto-oncogene; PLD, platinum doublet; PLT, platinum triplet (i.e., platinum doublet with bevacizumab); Peme., pemetrexed; Nivo., Nivolumab; Tra., trastuzumab; Per., pertuzumab; Vin., vinorelbine; Pac., paclitaxel; TDM1, trastuzumab emtansine, NA, not available. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Treatment duration with targeted therapy for hybrid capture (HC)-based next-generation sequencing (NGS)-identified drivers (weeks). Of 43 patients treated with targeted therapy after receipt of HC-based NGS results, 41 had available data on duration of targeted treatment. Each bar represents one patient, and the number of weeks of treatment is stated to the right of the bar. If initial targeted therapy was immediately followed by another targeted therapy addressing the same gene, the duration was measured as a whole for the sum of the durations of the treatment. *Other than exon 14 activating MET mutation. **Nonsensitizing EGFR mutation. ***EGFR high-volume amplification (×17). ALK, anaplastic lymphoma receptor tyrosine kinase gene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; MET, Mesenchymal-epithelial transition factor receptor tyrosine kinase gene; VUS, variation of unknown sequence; NTRK1, neurotrophic tyrosine kinase receptor type 1 gene; RET, ret proto-oncogene; NF1, neurofibromin 1 gene. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions


Download ppt "Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer  Anna Belilovski Rozenblum, MD, Maya."

Similar presentations


Ads by Google